Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Krikor who wrote (656)	12/15/1997 3:29:00 PM
From: Greg Spendjian	Read Replies (2) \| Respond to of 14101

This is probably the news that has got the stock moving nicely upwards. Good luck to all in the next few days ... then months as the FDA considers Pennsaid. Greg ---------------- <Picture: Business Wire > <Picture: [See PC Computing's Top Rated Investor Site. Click here!]> [ Business \| US Market \| Industry \| IPO \| S&P \| International \| PRNews \| BizWire \| Finance Home ] ------------------------------------------------------------------------ Monday December 15, 2:54 pm Eastern Time Company Press Release Dimethaid Research Files New Drug Application With FDA Seeks U.S. Marketing Approval For Pennsaid(TM) MARKHAM, Ontario--(BUSINESS WIRE)--Dec. 15, 1997--Dimethaid Research I(TSE:DMX. - news) Dimethaid Research Inc. announced today that it has filed a new drug application (NDA) with the United States Food and Drug Administration (FDA) for PENNSAID(tm), a topical non-steroidal anti inflammatory drug (NSAID) for the relief of osteoarthritic pain. This is the third application for approval of PENNSAID(tm), with earlier applications made to the Therapeutic Drugs Directorate (formerly Health Protection Branch) of Health Canada and the Medicines Control Agency of the United Kingdom. ''This is a very important milestone for us,'' said Rebecca Keeler, President and CEO of Dimethaid Research Inc. ''This submission culminates years of clinical study and means we are now entering the final stage prior to commercialization of PENNSAID(tm),'' Mrs. Keeler added. ''We intend to license PENNSAID(tm) to a commercial partner for worldwide sales and this significant development should also be beneficial to us in our continuing negotiations.'' Arthritis is a chronic condition that affects about 40 million Americans who receive an estimated 68 million prescriptions for medications to help alleviate their pain. According to the Centers for Disease Control, the direct medical cost of arthritis is estimated to be $15.2 billion per year. PENNSAID(tm) has been studied for the treatment of osteoarthritis, the most prevalent form of the disease. The Arthritis Foundation estimates that 15.8 million Americans suffer from osteoarthritis. PENNSAID(tm) is the first product utilizing Dimethaid's patented formulation for the delivery of active drug compounds through the skin and tissue to the site of pain. The expected benefits include localized relief at the site of application, few side effects and negligible toxicity. Most conventional methods of drug delivery, including oral, injection, and patch, deliver the active ingredient into the blood supply which in turn distributes the drug throughout the entire body, including the site of pain. This systemic distribution can lead to serious side effects such as gastro-intestinal bleeds and even death. In contrast, PENNSAID(tm) avoids the systemic distribution by using its unique carrier to access the micro-circulatory system within each cell to deliver the medication. In an ongoing Phase IV study in Canada, over 600 physician-investigators have prescribed PENNSAID(tm) to more than 2,200 patients in a primary care setting without any report of the serious adverse events that have been associated with the use of oral-NSAIDs. Dimethaid Research Inc. intends to pursue additional indications for this carrier in combination with other drugs Dimethaid Research Inc. is a pharmaceutical company engaged in the development and commercialization of innovative therapeutic products which work with the body's own healing mechanisms. The other major product under clinical development is an immune modulator called WF10, currently being tested for the treatment of HIV/AIDS and cancer. Dimethaid Research Inc. owns 20 percent of Oxo Chemie AG, the private Swiss company that owns WF10, and retains an option to further increase its position to 25 percent. ------------------------------------------------------------------------ Contact: Dimethaid Research Inc. Peter Block, 905/415-1446 e-mail: pblock@dimethaid.com or Dimethaid Research Inc. (Media contact) Vince Segreto, 905/415-1446 www.dimethaid.com